CONTACT US
Home > Inhibitors/Agonists>Drug-Linker Conjugates for ADC> > Deruxtecan
Deruxtecan

Deruxtecan

  • CAT Number: I020228
  • CAS Number: 1599440-13-7
  • Molecular Formula: C₅₂H₅₆FN₉O₁₃
  • Molecular Weight: 1034.05
  • Purity: ≥95%
Inquiry Now

Deruxtecan（Cat No.:I020228）, is an antibody-drug conjugate (ADC) used in cancer therapy. It consists of a monoclonal antibody that selectively targets cancer cells and a cytotoxic payload attached through a linker molecule. Specifically, deruxtecan incorporates the topoisomerase I inhibitor eaten as the cytotoxic agent. This ADC approach allows for targeted delivery of the cytotoxic payload to cancer cells, enhancing its efficacy while minimizing damage to healthy cells. Deruxtecan has shown promising results in clinical trials for the treatment of various cancers, including breast, lung, and gastric cancers.

Catalog Number I020228
CAS Number 1599440-13-7
Molecular Formula

C₅₂H₅₆FN₉O₁₃

Purity 95%
Reference

[1]. NOGUCHI, Shigeru, et al. METHOD FOR SELECTIVELY MANUFACTURING ANTIBODY-DRUG CONJUGATE. WO2017002776A1.<br>[2]. Ogitani Y, et al. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016 Jul;107(7):1039-46.

Request a Quote

Contact Us at MuseChem

We are committed to providing you with reliable, cost-effective solutions for your chemical needs, while ensuring your safety and comfort. Our team of experts is always available to answer your questions and help you navigate the complexities of the chemical industry.

Whether you're looking for a specific product or need help with a custom synthesis project, we're here to help you discover a new world of chemical possibilities. Contact us today to learn more about how we can assist you with all of your chemical needs.

Our goal is to make the process of ordering chemicals as seamless and hassle-free as possible. Let us know how we can assist you, and we'll get back to you as soon as possible. We look forward to hearing from you!